172 related articles for article (PubMed ID: 34208001)
1. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
[TBL] [Abstract][Full Text] [Related]
2. HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Liu Y; Liu X; Luo M; Li Y; Li H
Discov Med; 2023 Dec; 35(179):1035-1042. PubMed ID: 38058068
[TBL] [Abstract][Full Text] [Related]
3. Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells.
Cho S; Kim W; Yoo D; Han Y; Hwang H; Kim S; Kim J; Park S; Park Y; Jo H; Pyun JC; Lee M
Sci Rep; 2024 Jan; 14(1):1751. PubMed ID: 38243049
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.
Cruz SM; Iranpur KR; Judge SJ; Ames E; Sturgill IR; Farley LE; Darrow MA; Crowley JS; Monjazeb AM; Murphy WJ; Canter RJ
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542325
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in drug delivery systems for targeting cancer stem cells.
Duan H; Liu Y; Gao Z; Huang W
Acta Pharm Sin B; 2021 Jan; 11(1):55-70. PubMed ID: 33532180
[TBL] [Abstract][Full Text] [Related]
7. Integrated analyses for identification of a three-gene signature associated with Chaihu Shugan San formula for hepatocellular carcinoma treatment.
Xing JH; Tan RX; Huang FE; Tian N
J Cell Mol Med; 2024 Apr; 28(8):e18211. PubMed ID: 38613352
[TBL] [Abstract][Full Text] [Related]
8. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for HCC.
Chen P; Dong Z; Zhu W; Chen J; Zhou Y; Ye Q; Liao X; Tan Y; Li C; Wang Y; Pang H; Wen C; Jiang Y; Li X; Li B; Aimaier A; Lin L; Sun J; Hou J; Tang L; Hou J; Li Y
Hepatology; 2023 Oct; ():. PubMed ID: 37820061
[TBL] [Abstract][Full Text] [Related]
9. Cancer Stem Cells of Hepatocellular Carcinoma Are Suppressed by the Voltage-gated Calcium Channel Inhibitor Amlodipine.
Shiozaki A; Kurashima K; Kudou M; Shimizu H; Kosuga T; Takemoto K; Arita T; Konishi H; Yamamoto Y; Morimura R; Komatsu S; Ikoma H; Kubota T; Fujiwara H; Otsuji E
Anticancer Res; 2023 Nov; 43(11):4855-4864. PubMed ID: 37909988
[TBL] [Abstract][Full Text] [Related]
10. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
Li B; Li Y; Zhou H; Xu Y; Cao Y; Cheng C; Peng J; Li H; Zhang L; Su K; Xu Z; Hu Y; Lu J; Lu Y; Qian L; Wang Y; Zhang Y; Liu Q; Xie Y; Guo S; Mehal WZ; Yu D
Hepatology; 2024 Feb; 79(2):289-306. PubMed ID: 37540187
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?
Dunning NL; Laversin SA; Miles AK; Rees RC
Cancer Immunol Immunother; 2011 Aug; 60(8):1181-93. PubMed ID: 21688178
[TBL] [Abstract][Full Text] [Related]
12. Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α.
Qiu Y; Shan W; Yang Y; Jin M; Dai Y; Yang H; Jiao R; Xia Y; Liu Q; Ju L; Huang G; Zhang J; Yang L; Li L; Li Y
Cell Death Discov; 2019; 5():120. PubMed ID: 31341646
[TBL] [Abstract][Full Text] [Related]
13. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.
Rakké YS; Buschow SI; IJzermans JNM; Sprengers D
Front Immunol; 2024; 15():1357333. PubMed ID: 38440738
[TBL] [Abstract][Full Text] [Related]
14. Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells.
López-Grueso MJ; González R; Muntané J; Bárcena JA; Padilla CA
Antioxidants (Basel); 2019 Oct; 8(10):. PubMed ID: 31652503
[TBL] [Abstract][Full Text] [Related]
15. Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.
Kahraman DC; Hanquet G; Jeanmart L; Lanners S; Šramel P; Boháč A; Cetin-Atalay R
Medchemcomm; 2017 Jan; 8(1):81-87. PubMed ID: 30108693
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of six canine hepatocellular carcinoma cell lines.
Lee JY; Bae K; Kim JH; Han HJ; Yoon HY; Yoon KA
Front Vet Sci; 2024; 11():1392728. PubMed ID: 38840628
[TBL] [Abstract][Full Text] [Related]
17. The Great Escape: The Power of Cancer Stem Cells to Evade Programmed Cell Death.
Castelli V; Giordano A; Benedetti E; Giansanti F; Quintiliani M; Cimini A; d'Angelo M
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477367
[TBL] [Abstract][Full Text] [Related]
18. Effect of microserum environment stimulation on extraction and biological function of colorectal cancer stem cells.
Wang F; Zhao J; Zhang C; Yang B; Tian T; Tian M; Meng N; Xie W; Liu G; Zhu X; Su M; He Z; Liu Y; Tang D; Li Y
Discov Oncol; 2023 Aug; 14(1):156. PubMed ID: 37639070
[TBL] [Abstract][Full Text] [Related]
19. Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor-Initiating Stem-Like Cells.
Chen CL; Hernandez JC; Uthaya Kumar DB; Machida T; Tahara SM; El-Khoueiry A; Li M; Punj V; Swaminathan SK; Kirtane A; Chen Y; Panyam J; Machida K
Adv Sci (Weinh); 2023 May; 10(14):e2206812. PubMed ID: 36949364
[TBL] [Abstract][Full Text] [Related]
20. Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence.
Lopez DC; Fabian KP; Padget MR; Robbins YL; Kowalczyk JT; Lassoued W; Pastor DM; Allen CT; Gallia GL; Gulley JL; Hodge JW; London NR
Front Oncol; 2024; 14():1376622. PubMed ID: 38741774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
